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Abstract 
Objective To examine the burden of comorbidities prior to and after the diagnosis of 
systemic lupus erythematosus (SLE) and its impact on mortality. 
Methods We identified 1605 incident cases of SLE and 6284 matched controls from the UK 
primary care. The risks of comorbidities before (prevalence; odds ratios (ORs)) and after SLE 
diagnosis (incidence; hazard ratios (HRs)) and the impact of comorbidities at diagnosis on all-
cause mortality were estimated. 
Results At diagnosis SLE was associated with adjusted ORs (95% confidence interval [CI]) of 
2.25 (1.97-2.56), 3.37 (2.49-4.57) and 3.54 (1.89-6.63) for a Charlson comorbidity index of 1-
2, 3-4 and ≥5, respectively. Following diagnosis SLE also associated with increased risk of 
developing any comorbidity with an adjusted HR (95% CI) of 1.30 (95% CI, 1.13-1.49). At 
diagnosis SLE was associated with a greater risk of cancer, cardiovascular, renal, liver, 
rheumatological and neurological diseases as well as depression, anaemia and psoriasis. 
Risks of developing incident comorbidity in the categories of neoplasm, cardiovascular, 
genitourinary, metabolic/endocrine, gastrointestinal and hepatic diseases, chronic 
pulmonary diseases, musculoskeletal/connective tissue and neurological diseases were 
higher in SLE patients. People with SLE had higher mortality risk compared with controls, 
with adjusted HR of 1.91 (95% CI, 1.62-2.26); after further adjusting for comorbidities this 
reduced to 1.64 (1.37-1.97). Comorbidities at SLE diagnosis accounted for 27.6% of the 
apparent difference in mortality between SLE patients and matched controls. 
Conclusions People with SLE have increased risks of multiple comorbidities both prior to and 
after diagnosis and this contributes significantly to all-cause mortality.  
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Key message:  
1. Patients with SLE have a higher burden of multiple comorbidities at and after diagnosis. 
2. Comorbidities contribute significantly to all-cause mortality for SLE patients. 
3. A thorough search for comorbidities and observation are warranted for SLE patients from 
diagnosis. 
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Introduction  
Systemic lupus erythematosus (SLE) is a female-predominant prototypic autoimmune 
disease characterised by autoantibody production and subsequent multiple target organ 
damage.[1, 2] SLE can occur at any age and the course of the disease is highly diverse and 
unpredictable.[3] SLE can involve any part of the body but specific organ damage to the 
heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system define most 
clinical manifestations.[4] Both the multi-organ involvement of SLE and treatment for SLE 
frequently lead to an increased risk for comorbidities in affected patients[5] which 
collectively impacts adversely on the prognosis.[6] For example, people with SLE are 
reported to have an almost 80% higher mortality than the general population.[7]  
Current EULAR (European League against Rheumatism) recommendations for the 
management of SLE advise a high index of suspicion for the occurrence of comorbidities 
which should be promptly evaluated.[8] The ACR (American College of Rheumatology) 
guidelines for screening, treatment and management of lupus nephritis specifically 
recommend high vigilance for the control of hypertension and hypercholesterolemia.[9] 
However, other types of comorbidities may also associate with SLE.  For example, 
important comorbidities including hypertension, dyslipidaemia, diabetes, osteoporosis, 
avascular necrosis, and malignancies are also more common in people with SLE.[10] A recent 
population-based study using the Clinical Practice Research Data-link (CPRD), which is 
broadly representative of the UK general population documented a higher risk for 
cardiovascular diseases, stroke, end-stage renal disease, cancer, osteoporosis, and infection 
in people with SLE.[5]  
However, existing evidence predominantly comes from tertiary referral centres, which may 
be biased towards more severe cases, and additionally suboptimal selection of appropriate 
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controls hinders interpretation of the risks. Furthermore, how comorbidities at diagnosis 
impact on prognosis has not been examined. Therefore, we conducted this population-
based study using the CPRD to examine the risk of a comprehensive range of comorbidities 
in people with SLE compared with matched controls firstly at the time of the initial diagnosis 
of SLE and secondly during follow-up subsequent to diagnosis. We further examined the 
relative contribution of comorbidities to all-cause mortality. 
 
Methods  
This study used a hybrid design to combine both retrospective (prior to SLE diagnosis) and 
subsequent follow-up data (after initial diagnosis) from the CPRD. In addition, we modelled 
the influence of existing comorbidities on the all-cause mortality of SLE. The study was 
approved by the Independent Scientific Advisory Committee for MHRA Database Research 
(protocol 13_092). 
Data source 
We used the CPRD to examine the risk of comorbidities before and after the first diagnosis 
of SLE in incident patients identified between 1997 and 2005. The CPRD is an anonymised 
longitudinal database from the UK general practice containing individual level medical 
records, which was incepted in 1987 and includes approximately 14 million individuals in the 
UK up to 2017. In any calendar year covered, approximately 7% of the UK population were 
included in the database.[11] This database includes comprehensive information on 
demographics, lifestyle factors, medical diagnoses, results of investigations and 
examinations, operations, consultations, referrals and prescribed medications. The 
diagnostic coding system in CPRD is the Read code and the coding lists used in this study to 
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identify people with SLE and an array of comorbidities are shown in supplements. The 
database has been well validated for many diagnoses.[12-16] 
Definition of systemic lupus erythematosus 
People with a new diagnosis of SLE from 1997 to 2005 who had no evidence of SLE prior to 
the time of diagnosis (index date) and had at least a 3-year continuous registration prior to 
the index date were identified. To ensure the data quality recorded by each general 
practitioner (GP), we only included individuals registered with up-to-standard practices. 
Read codes which we used to identify SLE are listed in supplementary table 1. This code list 
was developed by our research team as described in our previous publications.[5, 7, 17] We 
selected Read codes for SLE or a subtype of SLE excluding cutaneous only lupus (such as 
discoid lupus) from the CPRD medical dictionary browser. Codes were excluded if they 
represented a diagnostic test, a scoring system, tuberculosis, lupus pernio, cutaneous-only 
SLE, drug-induced lupus or neonatal lupus. These code lists were developed by 3 
rheumatologists, 1 epidemiologist, 1 statistician and CPRD expert and 1 general practitioner. 
[17] We did not do external validation since GPs generally based on a confirmation by a 
hospital specialist and the positive predictive values of other autoimmune diseases on the 
CPRD were >90%.[1-3] 
Selection of controls 
The control group were participants from up-to-standard practices between 1997 and 2005 
who had at least 3 years of continuous registration and no record of SLE prior to the index 
date. We matched SLE cases 1:4 to controls by year of birth (±2 years), gender, general 
practice and year of first continuous registration (±2 years). The index date was the initial 
diagnosis date of SLE in cases, with the same date applied to their matched controls.  
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Study period 
The comorbidity status of people with SLE was ascertained in each of three periods: (1) 10 
years prior to index date; (2) 1 year prior to index date; and (3) after index date to the 
earliest date of occurrence of comorbidity, death, transfer from a participating general 
practice or 31 December 2013, whichever came first. The reason to include the two period 
prevalence (10 years and 1 year) prior to index date was to assess potential bias due to 
different observational periods for prevalence data. 
Comorbidity and mortality 
The general health status of both people with SLE and their matched controls was measured 
by the Charlson comorbidity index,[18] which contains 17 categories of comorbidities 
(myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular 
disease, dementia, chronic pulmonary disease, rheumatological disease (excluding SLE), 
peptic ulcer disease, mild liver disease, moderate or severe liver disease, diabetes mellitus 
(DM), DM with chronic complications, renal diseases, any malignancy (including leukaemia 
and lymphoma), metastatic solid tumour and HIV infection. We calculated the Charlson 
score for each study person at baseline by adding scores assigned to each specific diagnosis. 
Those coding lists were validated by Deyo et al. who produced a version for use with the 
International Classification of Diseases, Ninth Revision (ICD-9) based database,[19] which 
was the basis of the validated Read code version.[20]  
In addition, we also incorporated other comorbidities potentially associated with SLE, 
including anaemia, cardiac arrhythmias, depression, hypertension, hypothyroidism, gout, 
multiple sclerosis, neurological diseases, osteoarthritis, psoriasis, psychosis, urolithiasis and 
valvular heart disease. All comorbidities were further grouped into eight categories. The 
9 
 
case definitions of these conditions were based on physician diagnoses recorded as Read 
codes. These comorbidities were identified separately from records within each of the three 
study periods. The Charlson index at diagnosis was based on results from the 10-year period. 
Charlson comorbidity index was classified into categories: (1) 0, 1–2, 3–4 and ≥5 scores; and 
(2) dichotomised as 0 and ≥1 score. The code lists for these comorbidites are shown in 
supplementary table 2. 
Mortality was identified on the recording in the main database. The CPRD has developed an 
algorithm to identify death and date of death for deceased participants. We previously 
conducted a validation study comparing the mortality recorded in the CPRD main database 
and that in the death registry provided by the Office of National Statistics (ONS).[21] The 
positive and negative predictive value of a CPRD recorded death were 0.93 and 1.00, 
respectively. The difference between dates of death recorded in CPRD and ONS was less 
than 3 months in 98.5% of deceased patients.  
Statistical analysis 
We estimated the prevalence of a specific comorbidity by dividing the number of people 
ever diagnosed with a given comorbidity during the past 10-year period or 1-year period 
before the index date by the number of people with SLE or matched controls as 
denominators. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate 
the association between SLE and each coexisting medical condition. Conditional logistic 
regression was used to estimate ORs and 95% CIs considering covariates including body 
mass index (BMI) category, smoking status and alcohol consumption. Missing data were 
coded as ‘unknown’. Kaplan-Meier plots were used to estimate the cumulative probability of 
each comorbidity and all-cause mortality after the index date in people with SLE and those 
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without. Since some people may have comorbidities prior to SLE diagnosis, we only included 
people who were at risk for a given comorbidity, i.e., not having such comorbidity at index 
date, to estimate HRs of a specific comorbidity. Cox proportional hazards models were used 
to estimate HRs and 95% CIs were calculated for a Charlson index of one or more score, for 
each separate comorbidity and all-cause mortality. The HRs were adjusted by age, gender, 
index year, BMI categories, smoking status and alcohol consumption. We constructed three 
Cox proportional hazards models to examine HR for death associated with the diagnosis of 
SLE: model 1, unadjusted; model 2, adjusted for age, sex, index year, BMI class, smoking 
status and alcohol consumption; and model 3, adjusted for covariates in model 2 and all 
comorbidities which were already in existence at the time of the index date.  
We further examined the relative contribution of existing comorbidities at SLE diagnosis to 
the all-cause mortality using the concept of relative attenuation of rate ratios that was 
developed by Birkmeyer et al,[22] involving assessment of the relation between the SLE and 
all-cause mortality first, and then estimating the contribution by excluding and then 
including comorbidities at diagnosis. The relative contribution of existing comorbidities was 
computed as [HRa-HRc]÷[HRa-1], where HRa is the HR for all-cause mortality which was 
adjusted for all aforementioned covariates without consideration of pre-existing 
comorbidities and HRc is HR further adjusted for the full array of comorbidities at diagnosis 
of SLE. All statistical analyses were performed using SAS statistical software, V.9.4. 
 
Results  
During 1997 to 2005 we identified 1605 incident cases of SLE. Their mean age was 50.8 ± 
16.2 years and 1311 (81.7%) were women. The median observation periods (interquartile 
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range) before and after index date were 14 (8─23) and 9 (5─11) years respectively. They 
were age- and sex-matched to 6284 controls with the same age and sex structure (figure 1 
for flow chart). People with SLE tended to have a lower BMI and a higher prevalence of 
smoking. Patient characteristics at diagnosis are shown in Table 1. 
At index date the prevalence of people with a Charlson index ≥1 was significantly higher in 
people with SLE (38.07%) than in controls (20.35%; p<0.001). In an adjusted logistic 
regression model focussing on diagnoses in the 10-years prior to the index date, ORs (95% 
CIs) were 2.25 (1.97–2.56), 3.37 (2.49–4.57) and 3.54 (1.89–6.63) for Charlson scores 1-2, 3-
4 and ≥5 respectively (p for trend <0.001). The analysis restricted to diagnoses recorded in 
the one-year period prior to the index date provided a similar pattern of associations 
(supplementary table 2). After SLE diagnosis, the median time to first comorbidity in the 
Charlson index was 28 months (95% CI, 21-35 months) from the index date in people with 
SLE and 83 months (95% CI, 79-87 months) in controls (log-rank test p<0.001). The 
cumulative probability of having the first comorbidity in the Charlson index at 1, 2, 5 and 10 
years from index date were 42.4%, 45.0%, 51.8% and 61.7% in people with SLE and 22.4%, 
24.2%, 30.0% and 39.6% in controls (supplementary table 3). In addition, the cumulative 
probability of any increase in Charlson score was significantly greater in people with SLE than 
in controls and SLE was associated with an adjusted HR (95% CI) of 1.80 (1.62–2.26) for 
having a Charlson index ≥ 1. 
Renal diseases were particularly more common in people with SLE than matched controls at 
diagnosis, with an OR (95% CI) of 8.69 (5.21–14.50). Comparing to the estimates for 
comorbidities occurring in the period one year prior to SLE diagnosis (supplementary table 
2), SLE was associated with an OR (95% CI) of 19.57 (9.08-42.2) for renal diseases, suggesting 
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renal diseases often occur close to the time of SLE diagnosis. However, 9 out of 49 SLE 
patients who had existing renal diseases at diagnosis had kidney injury long before SLE 
diagnosis. After SLE diagnosis, the cumulative probability of having renal diseases were 4.39 
at 1 year and 6.78 at 5 years, which corresponded to a HR (95% CI) of 3.43 (2.38–4.93) when 
compared to controls. 
Other rheumatological diseases were common in SLE patient at diagnosis. When examining 
10 years prior to SLE diagnosis, 211 out of 1605 SLE patients (13.15%) had another 
rheumatological diagnosis (OR, 3.94). Restricting to one year prior to SLE diagnosis, there 
were still 108 (6.73%) patients who were given another rheumatological diagnosis (OR, 
4.73). After SLE diagnosis, there were 155 patients (11.12%) of at-risk patients who were 
given a new diagnosis of another rheumatological disease, the HR (95% CI) being 3.26 (2.45-
4.33) when compared to controls. Overall, the cumulative probability of having another 
rheumatological diagnosis was 15.60 at 1 year and 19.60 at 5 years after SLE diagnosis. The 
risk of other comorbidities at and after diagnosis in SLE patients comparing to controls are 
summarized in Table 2, supplementary table 3 and 4.  
After the index date, mortality at 5-years and 10-years from any cause was 8.28% and 
17.00% in people with SLE, compared to 4.43% and 10.29% in matched controls (log-rank 
test, p<0.001; supplementary table 5). Estimates of the effect of a diagnosis of SLE on 
mortality were attenuated after adjustment for demographic and lifestyle variables as well 
as comorbidity status at index date (table 3). After adjustment for age, sex, index year, BMI 
class, smoking status and alcohol consumption, SLE was associated with a HR of 1.91 (95% 
CI, 1.62–2.26). However, after adjustment for multiple comorbidities at diagnosis SLE 
remained strongly associated with all-cause mortality with a HR (95% CI) of 1.64 (1.37-1.97). 
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Thus, comorbidities at diagnosis of SLE accounted for 27.6% of the apparent difference in 
mortality between SLE patients and matched controls. The proportion of the apparent effect 
on mortality that was actually attributable to comorbidities at diagnosis was lower in men 
(20.6%) than in women (30.7%).  
Discussion   
This nationwide population-based study found an increased risk of comorbidity in people 
with SLE compared to matched controls at the time of initial diagnosis as well as an 
increased risk of incident comorbidity following diagnosis. Approximately half of people with 
SLE developed a condition included in the Charlson comorbidity index within 3 years of 
initial diagnosis, whereas it took 7 years for half of the controls to develop a relevant 
comorbidity. The pronounced differences in risks of an array of comorbidities between 
people with SLE prior to their initial diagnosis and matched controls suggest that a 
significant degree of organ damage and systemic consequences from SLE occur prior to 
initial diagnosis. This might be the reason for our finding that comorbidities at lupus 
diagnosis contributed 30% to all-cause mortality. Overall, the burden of comorbidity is 
substantially higher than controls at diagnosis of SLE and the risk of developing new 
comorbidity following diagnosis is also higher in people with SLE than in the general 
population. Furthermore, comorbidities contributed significantly to mortality. Therefore, a 
systematic screen for a range of comorbidities appears warranted in patients with SLE both 
at first diagnosis and subsequently during follow-up. 
Previous studies have reported an increased risk of multiple comorbidities in people with 
SLE but the temporal relationships with diagnosis of SLE are reported rarely. Our previous 
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study using CPRD data also found a greater comorbidity burden in prevalent SLE patients 
than controls, particularly for cardiovascular disease, stroke, renal failure, cancer, 
osteoporosis, and infection.[5] Other studies in general concur that the increased risk of 
comorbidities in selected categories, for example, cardiovascular and cerebrovascular 
diseases are consistently more common in people with SLE, regardless of age.[23-26] 
Chronic kidney disease is common in people with SLE and often leads to end-stage renal 
disease.[27, 28] Liver diseases, defined by biochemical or histological abnormalities, also 
seem more prevalent in people with SLE than controls.[29] The risk for cancer is also 
increased in people with SLE and a strong association between specific malignancies such as 
lung cancer, lymphoma, and other hematologic malignancies has been reported 
consistently.[30-32] People with SLE appear to be at greater risk of osteoporosis and 
subsequent fragility fractures compared to appropriate controls.[33, 34] Other categories of 
comorbidities that have been reported previously with established SLE include 
dyslipidaemia,[35] diabetes mellitus,[35] preclinical atherosclerosis,[36] and avascular bone 
necrosis.[37] The present study ascertained the risk of these comorbidities, as well as many 
other categories. Importantly we also identified the temporal course of the risk of 
comorbidities relative to the initial diagnosis of SLE.  
The higher comorbidity burden found both at 1 year and 10 years prior to diagnosis suggests 
that accrual of comorbidity is already greater in people with SLE than controls prior to the 
initial diagnosis. Several reasons may explain such a phenomenon. Both a pro-inflammatory 
status and immune aberration have been found to exist even before the clinical presentation 
of SLE. For example, subclinical atherosclerosis may underlie the risk of myocardial infarction 
close to or before SLE diagnosis. Delayed diagnosis may partly explain the higher risk of 
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certain comorbidities more closely linked to SLE, such as renal disease and CKD. However, 
the magnitude of odds ratios for specific comorbidities prior to diagnosis suggests that 
clinically occult specific organ damage may have occurred commonly prior to diagnosis. In 
addition, the accumulation of new comorbidities appears to be faster in people with SLE 
after diagnosis in both general and specific comorbidity categories. Therefore, at initial 
diagnosis of SLE, a comprehensive assessment of a wide range of comorbidities appears to 
be important, since some of these, such as osteoporosis and mild liver injury, present 
insidiously and their identification may influence management decisions. The continuous 
monitoring of the development of comorbidities also seems justified as part of standard care 
for people with SLE.  
A higher mortality risk in patient with lupus has long been recognised. A recent study using 
US national database and census data between 1968 and 2013 found a significant 
improvement in all-cause mortality but the reduction in mortality attributed to SLE was less 
than non-SLE causes.[38] A recent meta-analysis comprising 27,123 patients with SLE 
(among them 4,993 deaths) reported an 3-fold higher mortality risk in SLE patients 
compared with the general population, specific causes of death mainly being cardiovascular 
diseases, malignancy, infection and renal diseases.[39] It seems reasonable that 
comorbidities may impact on the mortality, in addition to SLE itself, however, the actual 
contribution has not been assessed before. In this study, we found that the comorbidities at 
diagnosis are a genuine risk factor for mortality, contributing approximately 30% to the risk 
of death. Since we also observed an accelerated incidence of comorbidities in SLE patients, 
their existence impacts significantly on the management and care of SLE patients, both at 
diagnosis and during follow-up.  
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The mechanisms underlying the relationships between SLE and the various associated 
comorbidities are complex and it is often difficult to discern causality, including from drugs 
(e.g. corticosteroids, immunosuppresants, NSAIDs) used to treat SLE following 
diagnosis .[40] Clinical implications of a greater comorbidity burden are simpler. The 
identification of comorbidity can be part of the diagnostic workup, as a consideration for 
management decisions and as a flag for prognosis.[41] Comorbidities such as CKD and 
anaemia are part of the classification criteria of SLE and awareness of the relationships in 
primary care between SLE and these closely related comorbidities may simplify the diagnosis 
of SLE. Using comorbidity as an indicator of prognosis is used widely in clinical practice. For 
example, the Charlson comorbidity index is used frequently to estimate comorbidity burden 
and to predict mortality.[18] Furthermore the presence of comorbidity may influence the 
management of SLE. Currently, EULAR recommendations for management of SLE advise a 
high index of suspicion and diligent follow-up for comorbidities in people with SLE.[42] The 
ACR guidelines for lupus nephritis also advise that special attention should be paid to 
possible presence of hypertension, hypercholesterolemia and vascular disease in people 
with SLE and that these should be treated appropriately.[9] However, our data indicate that 
the risks of comorbidities are not limited to cardiovascular or metabolic disease but involve 
multiple systems even at the time of initial diagnosis. Therefore, we suggest that a 
comprehensive comorbidity ‘checklist’, including all those that are more frequently present 
in people with SLE in this study, is justified to identify and treat comorbidities early and 
effectively to potentially improve patient outcomes. 
There are several limitations to this study. Firstly, there may be some misclassification bias 
since the identification of people with SLE was based on physician diagnosis, rather than 
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according to classification criteria. Similarly, there may have been some misclassification of 
comorbidities. However, many of these comorbidities are not typically diagnosed by general 
practitioners and such entries are likely to be guided by secondary care communication. 
Furthermore the diagnoses recorded in the CPRD have been validated previously with 
sufficient accuracy to support their use in clinical and epidemiological studies.[12] Although 
SLE has not been fully validated within the CPRD, validation of other autoimmune diseases 
within the CPRD has shown a good positive predictive value of over 90%.[43, 44] In addition, 
there is no reason to suspect a differential misclassification. Secondly, differential 
ascertainment bias between people with SLE and controls cannot be excluded, even though 
the estimates based on different lengths of previous observation produced similar results. 
Thirdly, residual confounding may exist. Fourthly, SLE manifestations may be misclassified as 
a disease entity. For example, multiple sclerosis as a comorbidity may be a misclassification 
of neuropsychiatric lupus. Fifthly, completeness of data across patients and across time is 
variable and the patterns or causes of missing are complex.[11] These missing data, such as 
alcohol consumption, may also have impact on the interpretation of our results. Race is also 
not available for all subjects in the CPRD. Only 27.1% of all patients in the CPRD have 
ethnicity recorded and among them 86% were white British.[45] 
In conclusion, a large proportion of people with SLE in the UK already have a greater than 
expected prevalence of comorbidity at the time of diagnosis and the subsequent risk of 
incident comorbidity following diagnosis is higher than in matched general population 
controls. All-cause mortality was higher in people with SLE and the increased risk may be 
caused both by SLE and its pre-existing or subsequent comorbidities. This study suggests 
that a thorough search for a broad range of comorbidity and subsequent vigilant observation 
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should be considered for all people with SLE from the date of first diagnosis. 
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